

This invention is a vaccine for the prevention of disease caused by nontypeable *H. influenzae*, which causes 25–40% of otitis media cases (middle ear infections) in children and other respiratory tract diseases in humans. The emergence of antibiotic-resistant bacteria has caused concern that treatment of otitis media will become more problematic. This invention offers a new approach to managing otitis media. The vaccine is composed of lipooligosaccharide, isolated from the surface of strains of nontypeable *H. influenzae* and treated with hydrazine to remove esterified fatty acids, covalently conjugated to an immunogenic carrier, such as tetanus toxoid. The conjugates have been shown to be nontoxic by the limulus amoebocyte assay, rabbit pyrogen test, and in a mouse lethal toxicity test. Antisera raised in rabbits immunized with the conjugate is bactericidal. (portfolio: Infectious Diseases—Vaccines, bacterial)

Materials And Methods for Detection and Treatment of Insulin Dependent Diabetes

NK Maclaren, AL Notkins, Q Li, MS Lan (NIDR)

Serial No. 08/514,213 filed 11 Aug 95 and

Serial No. 08/548,159 filed 25 Oct 95
Licensing Contact: J. Peter Kim, 301/496-7056 ext. 264

Insulin-dependent diabetes mellitus (IDDM) affects close to one million people in the United States. It is an autoimmune disease in which the immune system produces antibodies that attack the body's own insulin-manufacturing cells in the pancreas. Patients require daily injections of insulin to regulate blood sugar levels. The invention identified two proteins, named IA-2 and IA-2 β , that are important markers for type I (juvenile, insulin-dependent) diabetes. IA-2/IA-2 β , when used in diagnostic tests, recognized autoantibodies in 70 percent of IDDM patients. Combining IA-2/IA-2 β with other known markers increased the level of identification to 90 percent of individuals with IDDM. Moreover, the presence of autoantibodies to IA-2/IA-2 β in otherwise normal individuals was highly predictive in identifying those at risk of ultimately developing clinical disease. It is now possible to develop a rapid and effective test that can screen large populations for IDDM. In addition, IA-2/IA-2 β are candidates for immune tolerance and prevention of disease development.

Compositions Comprising Vitamin F
C Weinberger, S Kitareewan (NIEHS)

Serial No. 60/003,443 filed 08 Sep 95;
PCT/US96/15205 filed 06 Sep 96
Licensing Contact: Carol Lavrich, 301/496-7056 ext. 287

This invention relates to a collection of potential fat-soluble vitamins that may coordinate animal metabolism and development. RXR is a nuclear receptor that plays a central role in cell signaling by heterodimerizing with receptors binding thyroid hormones, retinoids and vitamin D. The invention and others of its compositions can be characterized as likely physiological effectors that may represent essential components for human nutrition and cell growth. Thus, the invention suggests that it may coordinate cell physiology through RXR-dependent hormone signaling pathways.

Macrocyclic Chelates, And Methods of Use Thereof

OA Gansow, K Kumar (NCI)
Serial No. 08/140,714 filed 22 Oct 93
U.S. Patent 5,428,154 issued 27 Jul 95
Licensing Contact: Raphe Kantor, 301/496-7735 ext. 247

Substituted 1,4,7,10-tetraaza cyclododecane-N,N', N'', N'''-tetraacetic acid (DOTA) has numerous desirable chelating qualities that make it useful for treating a number of cellular disorders. Presently available chelating agents lack specificity for their intended targets or do not adequately bind the chelated metal ion. These substituted DOTAs have a strong affinity for a number of metal ions. They can also be linked to biomolecules to form systems for delivering the chelated metal ion, which can be radiolabeled, to specific sites within a cell or organelle. (portfolio: Cancer—Therapeutics, immunoconjugates, conjugate chemistry)

The Cloning of Perilipin Proteins

C Londos, AS Greenberg, AR Kimmel, JJ Egan (NIDDK)
Serial No. 08/132,649 filed 04 Oct 93
U.S. Patent 5,585,462 to issue 17 Dec 96
Licensing Contact: Ken Hemby, 301/496/7735 ext. 265

Perilipins are found at the surface of lipid storage droplets of adipocytes. Little is known about the molecules on the surface of lipid droplets that may be involved in lipid metabolism and trafficking. The present invention provides isolated nucleic acid sequences which encode a family of perilipin proteins as well as isolated, purified perilipin proteins. These are useful as markers for differentiation of true adipocyte cells from non-adipocyte cells which, as a result of pathophysiological conditions, assume

adipocyte characteristics. (portfolio: Cancer—Research Materials)

Dated: December 6, 1996.

Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.

[FR Doc. 96-31883 Filed 12-16-96; 8:45 am]

BILLING CODE 4140-01-M

National Cancer Institute, Notice of Meeting

Notice is hereby given of the meeting of the National Cancer Institute Board of Scientific Advisors Prevention Working Group, January 30–31, 1997 at the Crystal Gateway Marriott, 1700 Jefferson Davis Highway, Arlington, Virginia.

This meeting will be closed to the public on January 30–31, 1997 from 8:30 a.m. to approximately 10 p.m. each day for the discussion of confidential issues relating to the review, discussion and evaluation of individual programs and projects conducted by the NCI Prevention Program. These discussions will reveal confidential trade secrets or commercial property such as patentable material, and personal information including consideration of personnel qualifications and performance, the competence of individual investigators and similar matters, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Information pertaining to the meeting may be obtained from Dr. Jack Gruber, Executive Secretary, National Cancer Institute Prevention Working Group, National Cancer Institute, 6130 Executive Blvd., EPN, Rm. 540, Bethesda, MD 20892 (301-496-9740).

Dated: December 10, 1996.

Paula N. Hayes,
Acting Committee Management Officer, NIH.
[FR Doc. 96-31879 Filed 12-16-96; 8:45 am]

BILLING CODE 4140-01-M

National Cancer Institutes; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting of the National Cancer Institute Special Emphasis Panel (SEP):

Name of SEP: Cooperative Family Registry for Epidemiologic Studies of Colon Cancer
Date: January 9–10, 1997
Time: 9:00 am

Place: Executive Plaza North, Room G 6130 Executive Boulevard Bethesda, MD 20852
Contact Person: Lalita D. Palekar, Ph.D. Scientific Review Administrator National Cancer Institute, NIH Executive Plaza North,